Gregory Mullen
Director de Operaciones en Ariceum Therapeutics GmbH .
Perfil
Gregory Edgar Mullen currently works at Theragnostics Ltd., as Director from 2017 and Ariceum Therapeutics GmbH, as Chief Operating Officer.
Cargos activos de Gregory Mullen
Empresas | Cargo | Inicio |
---|---|---|
Theragnostics Ltd.
Theragnostics Ltd. Medical SpecialtiesHealth Technology Part of Ariceum Therapeutics GmbH, Theragnostics Ltd. is a British company that develops and distributes diagnostic devices and therapeutics. The company is based in London, UK. The company was founded in 2013. Theragnostics was acquired by Ariceum Therapeutics GmbH on June 01, 2023 for $54.53 million. | Director/Miembro de la Junta | 16/01/2017 |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Director de Operaciones | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Theragnostics Ltd.
Theragnostics Ltd. Medical SpecialtiesHealth Technology Part of Ariceum Therapeutics GmbH, Theragnostics Ltd. is a British company that develops and distributes diagnostic devices and therapeutics. The company is based in London, UK. The company was founded in 2013. Theragnostics was acquired by Ariceum Therapeutics GmbH on June 01, 2023 for $54.53 million. | Health Technology |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Commercial Services |
- Bolsa de valores
- Insiders
- Gregory Mullen